JP2011511073A - Ｔｌｒ７活性化物質による膀胱の疾患の治療 - Google Patents

Ｔｌｒ７活性化物質による膀胱の疾患の治療 Download PDF

Info

Publication number
JP2011511073A
JP2011511073A JP2010545884A JP2010545884A JP2011511073A JP 2011511073 A JP2011511073 A JP 2011511073A JP 2010545884 A JP2010545884 A JP 2010545884A JP 2010545884 A JP2010545884 A JP 2010545884A JP 2011511073 A JP2011511073 A JP 2011511073A
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
substituted
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511073A5 (enExample
Inventor
デニス エー． カールソン，
ロレンゾ エム． レオニ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2011511073A publication Critical patent/JP2011511073A/ja
Publication of JP2011511073A5 publication Critical patent/JP2011511073A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2010545884A 2008-02-07 2009-02-06 Ｔｌｒ７活性化物質による膀胱の疾患の治療 Pending JP2011511073A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2699908P 2008-02-07 2008-02-07
PCT/US2009/000771 WO2009099650A2 (en) 2008-02-07 2009-02-06 Treatment of bladder diseases with a tlr7 activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014079326A Division JP2014129425A (ja) 2008-02-07 2014-04-08 Ｔｌｒ７活性化物質による膀胱の疾患の治療

Publications (2)

Publication Number Publication Date
JP2011511073A true JP2011511073A (ja) 2011-04-07
JP2011511073A5 JP2011511073A5 (enExample) 2012-03-15

Family

ID=40939077

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010545884A Pending JP2011511073A (ja) 2008-02-07 2009-02-06 Ｔｌｒ７活性化物質による膀胱の疾患の治療
JP2014079326A Pending JP2014129425A (ja) 2008-02-07 2014-04-08 Ｔｌｒ７活性化物質による膀胱の疾患の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014079326A Pending JP2014129425A (ja) 2008-02-07 2014-04-08 Ｔｌｒ７活性化物質による膀胱の疾患の治療

Country Status (12)

Country Link
US (1) US20090202626A1 (enExample)
EP (1) EP2259788A4 (enExample)
JP (2) JP2011511073A (enExample)
KR (1) KR20100137449A (enExample)
CN (1) CN102088974A (enExample)
AU (1) AU2009210655B2 (enExample)
BR (1) BRPI0907907A2 (enExample)
CA (1) CA2713438A1 (enExample)
EA (1) EA201001264A1 (enExample)
IL (1) IL207246A0 (enExample)
MX (1) MX2010008697A (enExample)
WO (1) WO2009099650A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502084A (ja) * 2014-01-10 2017-01-19 ユーロジェン ファーマ リミテッド 膀胱上皮内癌の治療における使用のためのイミキモドを含む医薬組成物
JP2017507912A (ja) * 2014-01-10 2017-03-23 シャンハイ バーディー バイオテック インコーポレイテッド 免疫療法のための化合物及び組成物
JP2025068055A (ja) * 2017-06-23 2025-04-24 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
EP2316032A1 (en) * 2008-08-20 2011-05-04 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8
WO2010088924A1 (en) * 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
KR101250419B1 (ko) 2010-12-16 2013-04-05 강원대학교산학협력단 Ｔｌｒ 작동제를 포함하는 유방암 방사선 치료 보조제
PT3590928T (pt) 2011-04-08 2021-08-19 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para o tratamento de infeções virais
JP6349256B2 (ja) 2011-11-09 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のためのプリン誘導体
SG11201404743TA (en) 2012-02-08 2014-09-26 Janssen R & D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
EA035790B1 (ru) 2012-07-13 2020-08-11 Янссен Сайенсиз Айрлэнд Юси Макроциклические пурины для лечения вирусных инфекций
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
EA035431B1 (ru) 2012-11-16 2020-06-15 Янссен Сайенсиз Айрлэнд Юси Гетероциклические замещенные производные 2-амино-хиназолина в качестве модуляторов tlr7 и/или tlr8 для лечения вирусных инфекций
SG11201506639XA (en) 2013-02-21 2015-09-29 Janssen Sciences Ireland Uc 2-aminopyrimidine derivatives for the treatment of viral infections
CN110590809B (zh) 2013-03-29 2022-04-19 爱尔兰詹森科学公司 用于治疗病毒感染的大环脱氮-嘌呤酮
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
PT3030563T (pt) 2013-06-27 2017-11-15 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
DK3027624T3 (en) 2013-07-30 2019-01-07 Janssen Sciences Ireland Uc THIENO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
EP3091978B1 (en) * 2014-01-10 2021-08-18 Urogen Pharma Ltd. Pharmaceutical compositions comprising imiquimod for use in the treatment of carcinoma in situ of the bladder
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
MA45539A (fr) 2016-07-01 2019-05-08 Janssen Sciences Ireland Unlimited Co Dihydropyranopyrimidines pour le traitement d'infections virales
ES2912945T3 (es) 2016-09-29 2022-05-30 Janssen Sciences Ireland Unlimited Co Profármacos de pirimidina para el tratamiento de infecciones virales y otras enfermedades
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
US12383700B2 (en) 2019-06-13 2025-08-12 Hollister Incorporated Reusable urinary catheter products
EP4628107A3 (en) 2019-06-25 2025-12-17 Hollister Incorporated Reusable urinary catheter products
CN112778372B (zh) * 2019-11-11 2025-09-23 苏州泽璟生物制药股份有限公司 咪唑并喹啉取代磷酸酯类激动剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療（ａ２）温熱療法と腫瘍溶解の同時治療（ａ３）
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5736553A (en) * 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
DK0553202T3 (da) * 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) * 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19505168A1 (de) * 1995-02-16 1996-08-22 Boehringer Mannheim Gmbh Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
DE19637209B4 (de) * 1996-09-12 2006-12-14 Siemens Ag Verfahren zum Steuern des Antriebsstrangs eines Kraftfahrzeugs und integrierte Antriebsstrangsteuerung
IL129319A0 (en) * 1996-10-25 2000-02-17 Minnesota Mining & Mfg Immune response modifier compounds for treatment of TH2 mediated and related diseases
CN1130363C (zh) * 1997-11-12 2003-12-10 三菱化学株式会社 嘌呤衍生物以及含有其作为有效成分的药物
DE69817393T2 (de) * 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
HU229441B1 (en) * 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL150594A0 (en) * 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
US6533645B2 (en) * 2000-01-18 2003-03-18 Applied Materials, Inc. Substrate polishing article
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
AU1227302A (en) * 2000-09-15 2002-03-26 Virco Nv System and method for optimizing drug therapy for the treatment of diseases
WO2002030399A2 (en) * 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
US20020127224A1 (en) * 2001-03-02 2002-09-12 James Chen Use of photoluminescent nanoparticles for photodynamic therapy
ES2278016T3 (es) * 2001-04-09 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Compuestos guanidino como agonistas del receptor de melanocortina 4 (mc4-r).
US7157465B2 (en) * 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
WO2003037860A2 (en) * 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
MXPA05003193A (es) * 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US20070161582A1 (en) * 2003-08-08 2007-07-12 Dusan Mijikovic Pharmaceutical compositions and methods for metabolic modulation
JP2007504232A (ja) * 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
MXPA06002997A (es) * 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
US8012964B2 (en) * 2004-03-26 2011-09-06 Dainippon Sumitomo Pharma Co., Ltd. 9-substituted 8-oxoadenine compound
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
WO2006065234A1 (en) * 2004-12-10 2006-06-22 University Of Pittsburgh Use of lipid and hydrogel vehicles for treatment and drug delivery
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
JPWO2007034817A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
US20090105212A1 (en) * 2005-09-22 2009-04-23 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
EP2700638A1 (en) * 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US20080008682A1 (en) * 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
CN101790380B (zh) * 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
CA2691444C (en) * 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
WO2009052310A1 (en) * 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JP5694345B2 (ja) * 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
US20120003298A1 (en) * 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
AU2011247358B2 (en) * 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
AU2011295853A1 (en) * 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
WO2012038058A1 (en) * 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519784A (ja) * 2003-01-28 2006-08-31 シャンハイ、サンウエイ、バイアテク、カムパニ、リミティド 原発癌および転移癌に対する治療（ａ２）温熱療法と腫瘍溶解の同時治療（ａ３）
WO2007024707A2 (en) * 2005-08-22 2007-03-01 The Regents Of The University Of California Tlr agonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502084A (ja) * 2014-01-10 2017-01-19 ユーロジェン ファーマ リミテッド 膀胱上皮内癌の治療における使用のためのイミキモドを含む医薬組成物
JP2017507912A (ja) * 2014-01-10 2017-03-23 シャンハイ バーディー バイオテック インコーポレイテッド 免疫療法のための化合物及び組成物
JP2025068055A (ja) * 2017-06-23 2025-04-24 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物

Also Published As

Publication number Publication date
CA2713438A1 (en) 2009-08-13
WO2009099650A2 (en) 2009-08-13
WO2009099650A4 (en) 2010-01-14
WO2009099650A3 (en) 2009-10-22
IL207246A0 (en) 2010-12-30
MX2010008697A (es) 2010-12-07
US20090202626A1 (en) 2009-08-13
KR20100137449A (ko) 2010-12-30
AU2009210655B2 (en) 2013-08-15
EP2259788A4 (en) 2011-03-16
EP2259788A2 (en) 2010-12-15
JP2014129425A (ja) 2014-07-10
EA201001264A1 (ru) 2011-04-29
CN102088974A (zh) 2011-06-08
BRPI0907907A2 (pt) 2015-07-28
AU2009210655A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
JP2011511073A (ja) Ｔｌｒ７活性化物質による膀胱の疾患の治療
JP5425642B2 (ja) 合成ｔｌｒアゴニストの結合体およびそのための使用
JP2013040209A (ja) Ｔｌｒアゴニスト
KR20150132306A (ko) 염증, 자가면역 장애 및 통증의 치료 방법
CN103118682A (zh) 合成tlr7激动剂的磷脂缀合物的用途
JP2014532727A (ja) 疎水性カンプトテシン誘導体の医薬組成物
US20230149560A1 (en) Lipid compositions for delivery of sting agonist compounds and uses thereof
JP6483736B2 (ja) 癌の治療のためのキナーゼ阻害剤
US20210038742A1 (en) Conjugation of tlr7 agonist to nano-materials enhances the agonistic activity
EP4117660B1 (en) Methods of modulating t-cell activation and treating chronic heart failure using carboranes
Liang et al. A Programmable Nanoreactor Orchestrates Cascade of DNA Sensing to Amplify cGAS‐STING Activation for Cancer Immunotherapy
BRPI0807196B1 (pt) Compostos 6-amino-8-hidróxipurin-9-ilbenzil substituídos, e, usos dos mesmos
JP2022527296A (ja) 卵巣の悪性ラブドイド腫瘍および卵巣高カルシウム血症型小細胞がんを処置する方法
HK1196556B (zh) 疏水性喜樹鹼衍生物的藥物組合物
HK1126114A (en) Tlr agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140820